GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Ignore the noise in GLP-1 stocks. Find the best value instead.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to healthcare and ...

Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving SolutionsSurge Driven by Ozempic and Zepbound Prescription ...

Giftify (GIFT) announced a significant increase in gift card sales following its announcement of a smart savings program for GLP-1 diabetes and ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...